Heteroaryl substituted titanocenes as potential anti-cancer drugs
Sweeney, N., Gallagher, W.M., Muller-Bunz, H., Pampillon, C., Strohfeldt, K. and Tacke, M. (2006) Heteroaryl substituted titanocenes as potential anti-cancer drugs. Journal of Inorganic Biochemistry, 100 (9). pp. 1479-1486. ISSN 0162-0134
Full text not archived in this repository.
To link to this article DOI: 10.1016/j.jinorgbio.2006.04.006
From the reaction of Super Hydride (LiBEt3H) with 6-(furyl)fulvene (1a), 6-(thiophenyl)fulvene (1b) or 6-(N-methyl-pyrrole)fulvene (1c) the corresponding lithium cyclopentadienide intermediates (2a-c) were obtained. These intermediates were reacted with titanium tetrachloride and bis-[(furyl-2-cyclopentadienylmethane)] titanium(IV) dichloride (3a) and bis-[(thiophenyl-2-cyclopentadienylmethane)] titanium(IV) dichloride (3b) and bis-[(N-methylpyrrole-2-cyclopentadienylmethane)] titanium(IV) dichloride (3c) were obtained and subsequently characterised by X-ray crystallography. When titanocenes 3a-c were tested against pig kidney (LLC-PK) cells inhibitory concentrations (IC50) of 1.6 x 10(-4) M, 1.5 x 10(-4) M and 9.1 x 10(-5) M, respectively, were observed. These values represent improved cytotoxicity against LLC-PK, when compared to their corresponding ansa substituted analogues and also in comparison to unsubstituted titanocene dichloride. (c) 2006 Elsevier Inc. All rights reserved.